Nasopharyngeal carcinoma in children and young adults—Beyond 5‐year survival

Ben-Ami, Tal; Ash, Susan; Ben-Harosh, Miri; Gavriel, Haim; Weintraub, Michael; Revel‐Vilk, Shoshana; Ben-Arush, Myriam

doi:10.1002/pbc.28494

Cited by 11 publications

(28 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to a long life expectancy, children and adolescents are at an increased risk for second malignancies. 9,14,18,20,28 Most second malignancies have been reported in the irradiated site. In a population-based study from Taiwan, the incidence of second primary cancer was 3% among 23,639 NPC patients; second primary cancers were most common in the oral/pharyngeal region and skin.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Nasopharyngeal carcinoma in children: Multimodal treatment and long‐term outcome of 92 patients in a single center over a 28‐year period

Kebudi

Buyukkapu

Görgün

et al. 2021

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Objectives:The aim of the study was to evaluate the long-term outcome and late effects in pediatric patients with nasopharyngeal carcinoma (NPC) treated with neoadjuvant chemotherapy (NACT), followed by radiotherapy (RT).Methods: Ninety-two children (65 male, 27 female) diagnosed with NPC between 1989 and 2017 in the Istanbul University, Institute of Oncology were evaluated retrospectively. NACT consisted of three cycles of cisplatin-containing regimen every 3 weeks, followed by RT. Results:The median age was 13 years (5-18 years). Most had locoregionally advanced disease (stage III/IVA/IVB) and five had distant metastases at presentation. At a median follow-up of 108 months (3-332 months), 5-and 10-year overall survival rates and event-free survival rates were 87.5%, 79.7% and 82.1%, 78.9%, respectively. Three patients with distant metastasis are long-term survivors. Thirteen patients relapsed at a median of 8 months (2-23 months). Hypothyroidism (36%) and xerostomia (25%) were the most frequent long-term treatment-related toxicities. Nine second malignancies developed in eight patients, eight in the irradiated field at a median of 14 years (range 5-26 years), five of whom are long-term survivors after curative surgery.Conclusions: Three courses of cisplatin-containing NACT, followed by RT lead to high survival and locoregional control rate in advanced stage NPC in children. Patients with distant metastasis should also be treated with curative intent by systemic chemotherapy and locoregional radiotherapy. Patients should be followed closely for recurrences and long-term morbidities including second malignancies, which may be treated with curative surgeries if diagnosed early.

show abstract

Section: Discussionmentioning

confidence: 99%

“…9,10,[12][13][14][15][16][17]23 Most children with NPC will become long-term survivors and many will carry the risk of treatment-related late effects, including second malignancies. [17][18][19][20] Information on late effects occuring decades after treatment are scarce in children.…”

Section: Introductionmentioning

confidence: 99%

Nasopharyngeal carcinoma in children: Multimodal treatment and long‐term outcome of 92 patients in a single center over a 28‐year period

Kebudi

Buyukkapu

Görgün

et al. 2021

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…As the treatment protocols improve, overall survival rates of patients in nonmetastatic condition have climbed up to more than 80%. 3 Although current treatment leads to a favorable survival rate, chemo-resistance emerges as a difficult problem in curing recurrent NPC patients. 4 Messenger RNA (mRNA) has been proved to affect malignant behaviors of NPC.…”

Section: Introductionmentioning

confidence: 99%

CircKIAA0368 Promotes Proliferation, Migration, and Invasion by Upregulating HOXA10 in Nasopharyngeal Carcinoma

Chen

Gong

et al. 2022

Am J Rhinol�Allergy

View full text Add to dashboard Cite

Background: Nasopharyngeal carcinoma (NPC) represents a head and neck cancer caused by cancerization of nasal epithelial cells. HOXA10 has been identified to promote proliferation and invasion of NPC cells, but its regulatory mechanism has not been well discussed. Published research work has also pointed out that circular RNAs (circRNAs) could regulate mRNAs to affect NPC tumorigenesis and development. Aim: To explore the roles of HOXA10 and its specific regulatory mechanism regarding circRNAs in NPC. Methods: Reverse transcription polymerase chain reaction and western blot were applied to test gene expression. Functional assays were used to evaluate changes in NPC cell phenotypes. Mechanism assays were done to verify RNA-RNA or RNA-protein interaction. Results: HOXA10 was highly expressed in NPC tissues and cell lines. Moreover, HOXA10 knockdown could restrict NPC cell proliferation, invasion, migration, and epithelial–mesenchymal transition. CircKIAA0368 was upregulated in NPC cells and could elevate HOXA10 expression by sponging miR-6838-5p. Furthermore, circKIAA0368 was unveiled to competitively bind to p300/CREB-binding protein-associated factor (PCAF) to repress acetylation and degradation of HOXA10 protein. Conclusion: CircKIAA0368 upregulates HOXA10 expression via miR-6838-5p and PCAF, consequently promoting NPCcell and tumor growth.

show abstract

“…Thanks to multimodal treatment strategies combining chemotherapy and RT, prognosis of pediatric NPC has improved, reaching more than 90% overall survival (OS) and progression‐free survival (PFS) at 5 years, even with primary advanced locoregional disease 11–14,17,21 . Nevertheless, most of the survivors of childhood NPC will be burdened with long‐term treatment‐related effects, with a 15‐year cumulative incidence of any morbidity of 84% according to retrospective studies from St. Jude Children's Research Hospital and Israel 15,22 …”

Section: Introductionmentioning

confidence: 99%

Nasopharyngeal carcinoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations

Ben-Ami

Kontny

Surun

et al. 2021

Pediatric Blood & Cancer

Self Cite

View full text Add to dashboard Cite

Nasopharyngeal carcinoma (NPC) is a rare pediatric tumor. Collaborative studies performed over the last decades showed improved results compared to historical data, but standardized guidelines for diagnosis and management of pediatric NPC are still unavailable. This study presents a European consensus guideline for the diagnosis and treatment of pediatric NPC developed by the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT). Main recommendations include induction chemotherapy with cisplatin and 5‐flurouracil, concomitant chemoradiotherapy in advanced disease, and to consider maintenance treatment with interferon beta (IFN‐β) for selected high‐risk patients. Dose adjustments of radiotherapy based on response to induction chemotherapy may decrease the rates of long‐term treatment‐related complications that affect most of the survivors.

show abstract

Nasopharyngeal carcinoma in children and young adults—Beyond 5‐year survival

Cited by 11 publications

References 20 publications

Nasopharyngeal carcinoma in children: Multimodal treatment and long‐term outcome of 92 patients in a single center over a 28‐year period

Nasopharyngeal carcinoma in children: Multimodal treatment and long‐term outcome of 92 patients in a single center over a 28‐year period

CircKIAA0368 Promotes Proliferation, Migration, and Invasion by Upregulating HOXA10 in Nasopharyngeal Carcinoma

Nasopharyngeal carcinoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations

Contact Info

Product

Resources

About